Diasorin S.p.a. · MIL:DIA
Diasorin — Q1 2026 Earnings Presentation
23 slides from Diasorin's earnings presentation, May 8, 2026
Slide 1: Q1 2026 Results
XY Oiasorin Q1 2026 RESULTS May 8, 2026
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to comments of any person presenting it. This document, taken together you solely for your information and may not be reproduced, in whole or in
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Business Highlights
BUSINESS HIGHLIGHTS +) Diasorin
Slide 5: Business highlights: Jan–Mar 2026 milestones
Jan Feb Mar 2026 2026 2026 Delta Hepatitis LIAISON QuantiFERON-TB Gold Plus II U.S. Market U.S. Market Authorization request LIAISON NES Group A Strep U.S. Market Distribution agreement Fisher Scientific Extension of the agreement with LabCorp Distribution agreement McKesson LIAISON NES Immuno + Mol
Slide 6: Financial Highlights
FINANCIAL HIGHLIGHTS +) Diasorin
Slide 7: Q1'26 Revenue Variances
Q1’26 Revenue Variances Q1’26 Group revenues (figures in €/million - percentage variances @CER’25) CERPY Spot EUR/USD FX: 1.05 Note: YoY variations are presented using 2025 constant exchange rates. Both absolute figures and percentages are rounded to the nearest whole number 7 Indicative graphic onl
Slide 8: Q1'26 Immunodiagnostic Revenue Variances
Q1’26 Immunodiagnostic Revenue Variances Q1’26 Immunodiagnostic Revenues (figures in €/million - percentage variances @CER’25) CERPY Spot EUR/USD FX: 1.05 Base Business (excluding China): By region: • Excellent performance of specialty test sales and continued success of the U.S. hospital strategy,
Slide 9: Q1'26 Molecular Diagnostic Revenue Variances
Q1’26 Molecular Diagnostic Revenue Variances Q1’26 Molecular Diagnostics Revenues (figures in €/million - percentage variances @CER’25) Lowplex Multiplex CERPY Spot EUR/USD FX: 1.05 Automated multiplexing: LIAISON MDX targeted: • Business impacted by flu seasonality due to current menu (RSP panel on
Slide 10: Automated Multiplexing: LIAISON PLEX
Automated Multiplexing: LIAISON PLEX LIAISON PLEX CUSTOMERS: >150 (65% flex vs. 35% fixed) BY NUMBER OF CUSTOMERS BY REVENUE CONTRIBUTION • 10% commercial labs • 30% commercial labs • 90% hospital labs • 70% hospital labs LIAISON PLEX COMMERCIAL LAUNCH UPDATE: • Commercial team fully established and
Slide 11: Q1'26 LTG Revenue Variances
Q1’26 LTG Revenue Variances Q1’26 LTG Revenues (figures in €/million - percentage variances @CER’25) CERPY Spot EUR/USD FX: 1.05 Life Science clients: • Performance impacted by unfavorable market conditions Diagnostics clients: • Tough comparison with Q1’25, which had benefited from the timing of sh
Slide 12: Q1'26 Profitability Profile
Q1’26 Profitability Profile Net Revenues and Adj. EBITDA data @ current exchange rates; Adj. EBITDA Margin @ CER 34% 31% Net 313 In Q1’26, Adjusted1 EBITDA2 Margin was equal to 31% @ CER, Revenues 287 reflecting an unfavorable mix driven by shipment timing in Licensed Adjusted1 Technologies, pricing
Slide 13: FY 2026 Company Guidance and 2026 Outlook
FY 2026 COMPANY GUIDANCE AND 2026 OUTLOOK +) Diasorin
Slide 14: FY'26 Guidance Confirmed
FY’26 Guidance Confirmed FY’26 GUIDANCE (@CER 2025) CERPY Spot EUR/USD FX: 1.05 Avg. Expected 2026 EUR/USD FX: 1.18 (Source: Bloomberg) as of May 7, 2026 1 cent of difference between EUR and USD over 12 months has an impact on: • FY Revenue of ca. €/mln 6-8 • FY EBITDA of ca. €/mln 2-3 1 With refere
Slide 15: FY'26 Top Line Guidance @CER2025
FY’26 Top Line Guidance @CER2025 Revenue Guidance FY’26 Between +5% and +6% 1,195 €/mln • LTG: diagnostic customers are expected to grow at a LSD-to-MSD% rate, +LSD% offsetting the continued weakness in the Life Science business. LTG 165 €/mln • Molecular Diagnostics: growth driven by the launch of
Slide 16: FY'26 Growth Trajectory by Quarter
FY’26 Growth Trajectory by Quarter 1Q26 2Q26 3Q26 4Q26 • Immunodiagnostics: steady growth across different quarters in FY’26 as a result of the unique specialty menu and the hospital strategy, partially compensated by the normalization of volumes in Europe, with the exception of some tough compariso
Slide 17: Financial Schemes
FINANCIAL SCHEMES +) Diasorin
Slide 18: Income Statement
Income Statement Q1 Change Amounts in millions of euros 2025 2026 amount % Net Revenues 313 287 -26 -8% Cost of sales (109) (101) +7 -7% Gross profit 205 186 -19 -9% 65% 65% -61 bps Total operating costs (132) (129) +2 -2% non recurring amount (1) (1) -0 +55% EBIT 73 56 -17 -23% 23% 20% -367 bps Net
Slide 19: Balance Sheet
Balance Sheet Amounts in millions of euros 12/31/2025 03/31/2026 Change Goodwill and intangibles assets 1,790 1,818 +28 Property, plant and equipment 256 265 +9 Other non-current assets 42 42 -0 Net working capital 325 343 +18 Other non-current liabilities (257) (261) -4 Net Invested Capital 2,157 2
Slide 20: Cash Flow Statement
Cash Flow Statement Q1 Amounts in millions of euros 2025 2026 Cash and cash equivalents at the beginning of the period 344 166 Cash provided by operating activities 71 58 Cash provided/(used) in investing activities 8 16 Cash provided/(used) in financing activities (58) (39) Net change in cash and c
Slide 21: March 2026 Reconciliation to Consolidated Financial Statements
March 2026 Reconciliation to Consolidated Financial Statements Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 186 86 56 38 % on Revenues 65% 30% 20% 13% Adjustments “One-off” costs related to non recurring events 1 3 2 2 Depreciation of Luminex intangi
Slide 22: March 2025 Reconciliation to Consolidated Financial Statements
March 2025 Reconciliation to Consolidated Financial Statements Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 205 106 73 52 % on Revenues 65% 34% 23% 17% Adjustments “One-off” costs related to non recurring events 1 1 1 1 Depreciation of Luminex intang
Slide 23: Slide 23